ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 270

HIV Infection and Avascular Necrosis in the Antiretroviral Era

Yasir Abdulqader1, Muhsen Al-ani2 and Konstantinos Parperis3, 1Internal Medicine, Maricopa Integrated health system, Phoenix, AZ, 2Internal Medicine, Maricopa Integrated Health System and University of Arizona College of Medicine, Phoenix Campus, phoenix, AZ, 3Rheumatology, Maricopa Integrated Health System and University of Arizona College of Medicine, Phoenix Campus, phoenix, AZ

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Avascular necrosis, immune deficiency and infection

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Infection-related Rheumatic Disease Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Infection with the HIV has been associated with an increased risk of developing avascular necrosis (AVN), however there are only few studies in the US that analyzed the frequency and risk factors of the AVN in HIV patients on antiretroviral therapy (ART). The aim of this study was to determine the prevalence of AVN in well-controlled HIV-infected patients who were receiving antiretroviral treatment and evaluate potential risks factors including HIV medications.

Methods:

: A retrospective review of our medical record database over a 6 year period was conducted using ICD-9 and ICD-10 codes. Three thousand patients with chronic HIV infection on ART that had more than 2 visits in the HIV clinic were identified. Individual electronic patient charts were reviewed and we identified patients diagnosed with AVN that was confirmed by magnetic resonance imaging studies. We collected data regarding patient’s demographic characteristics, co-morbidities, T-helper lymphocytes with CD4 cell surface marker count, HIV RNA viral load and antiretroviral regimen. Two hundred randomly selected HIV-infected patients on ART without a diagnosis of AVN were used as a control group. Group differences were statistically compared and presented using Mann-Whitney U and Fisher’s exact test.

Results:

Forty two out of 3000 HIV patients (1.4 %) with AVN were identified (mean age of 49.5 years, 87% male). The most commonly involved joint was the hip (80%, n=34), followed by the glenohumeral (7.5%, n=4), femoral condyle (4.7%, n=2) and ankle (4.7%, n=2). Associated co-morbidities in patients with AVN included hyperlipidemia (21%, n=9), hypertension (19%, n=8), COPD/asthma(12%,n=5), hepatitis C (12%,n=5). All the patients with COPD/asthma have been treated with corticosteroids. Ten patients underwent joint replacement (23%), 4 core decompression surgery (9%) and the rest non-operative management.

Compared with the 200 HIV control patients, the patients with AVN were older (mean age of 49.5 vs. 42.7 years; p<0.01), had a history of COPD treated with corticosteroids (p= 0.02) and had a longer duration of HIV infection (mean duration of 16.8 vs.10.3 years; p<0.01). Patients who developed AVN were more likely to be receiving integrase strand transfer inhibitors (66%) compare to those who never received integrase inhibitors (20%; p<0.01). No differences were found between ANV patients and controls with respect to CD4 cell counts or viral load

Conclusion:

AVN remains one of the most frequent musculoskeletal complication in HIV patients. Potential risk factors associated with the development of AVN in HIV patients were older age, longer duration of HIV infection, history of COPD/asthma, corticosteroid use and the use of ART regimens containing integrase strand transfer inhibitors.


Disclosure: Y. Abdulqader, None; M. Al-ani, None; K. Parperis, None.

To cite this abstract in AMA style:

Abdulqader Y, Al-ani M, Parperis K. HIV Infection and Avascular Necrosis in the Antiretroviral Era [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/hiv-infection-and-avascular-necrosis-in-the-antiretroviral-era/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hiv-infection-and-avascular-necrosis-in-the-antiretroviral-era/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology